<DOC>
	<DOCNO>NCT02580708</DOCNO>
	<brief_summary>The purpose study evaluate safety anti-tumor effect rociletinib administer combination trametinib .</brief_summary>
	<brief_title>A Phase 1/2 Study Safety Efficacy Rociletinib When Administered Combination With Trametinib Patients With Activating EGFR Mutation-positive Advanced Metastatic Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>This Phase 1/2 , open-label , non randomize , multicenter study evaluate safety efficacy rociletinib administer combination trametinib . This study conduct 2 phase : Phase 1 : This dose escalation phase study . Phase 1 determine MAD MTD RP2D combination rociletinib trametinib , evaluate safety tolerability PK profile EGFRm NSCLC patient fail least one prior EGFR TKI . Phase 2 : This dose expansion phase . Phase 2 evaluate preliminary efficacy pharmacodynamics combination rociletinib trametinib RP2D two subset EGFRm NSCLC patient .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<criteria>Written informed consent Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) approve ICF studyspecific evaluation Histologically cytologically confirm metastatic unresectable locally advanced NSCLC EGFR activate mutation ( exclude exon 20 insertion ) ; measurable disease per RECIST 1.1 Prior treatment EGFR TKI ; Phase 2 , prior treatment T790Mdirected EGFR TKI patient Group B . Previous chemotherapy allow ; Phase 2 , immediate prior therapy must EGFR TKI Patient willingness undergo tumor biopsy baseline treatment ( optional Phase 1 ; mandatory Phase 2 ) Eastern Cooperative Oncology Group ( ECOG ) performance status 01 ; life expectancy least 3 month Adequate hematological biological function ; LVEF â‰¥50 % Documented evidence tumor exon 20 insertion , small cell transformation , MET amplification Leptomeningeal carcinomatosis untreated symptomatic CNS metastasis ( asymptomatic CNS metastasis allow clinically stable without requirement steroid within 2 week ) Known preexist interstitial lung disease pneumonitis Concurrent use QTprolonging medication Uncontrolled diabetes ( HA1C &gt; 10 % ) despite optional therapy Cardiac abnormality : Clinically significant abnormal 12lead ECG , QT interval correct use Fridericia 's method ( QTcF ) &gt; 450 m Inability measure QT interval ECG Personal family history long QT syndrome Implantable pacemaker implantable cardioverter defibrillator Resting bradycardia &lt; 55 beats/min Inability swallow oral study treatment gastrointestinal disease condition would preclude adequate absorption study treatment Presence serious unstable concomitant systemic disorder incompatible clinical study ( eg , substance abuse ; uncontrolled intercurrent illness include active infection ; arterial thrombosis ; unstable respiratory , hepatic , renal cardiac disease ; active malignancy ) Pregnant breastfeed female male female patient refuse use adequate contraception study 16 week last dose study treatment Any contraindication , allergy , hypersensitivity rociletinib , trametinib , excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>